Literature DB >> 18217999

A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1.

J Garcia-Perez1, M Perez-Olmeda, S Sanchez-Palomino, P Perez-Romero, J Alcami.   

Abstract

OBJECTIVE: In heavily pretreated patients, resistance mutations arise in both protease (PR) and reverse transcriptase (RT) sequences; however, the relative impact of PR and RT mutations on viral fitness cannot be evaluated with the majority of systems. To address this issue we have developed a model based on recombinant viruses (RVs) that allows the analysis of the replication capacity (RC) of viral populations in which PR and RT are cloned either in combination or separately.
METHODS: RVs were generated for full-length polymerase (pol) gene, PR or RT sequences from nine naïve and 14 heavily pretreated HIV-infected patients in therapeutic failure. The relative RC was assessed by comparing luciferase activity between mutant RV and wild-type (wt) isolates.
RESULTS: A strong decrease (>60%) in the RC of the pol RV population was observed in the 14 heavily pretreated patients as compared with the wt RVs. The analysis of PR and RT RVs from these patients showed that the decrease in RC was mainly attributable to PR sequences in three of these 14 patients and to RT sequences in seven of these patients. In the four remaining patients, PR and RT sequences independently reduced the RC of the RVs to similar extents.
CONCLUSIONS: Different patterns of mutations in either PR or RT have a strong impact on RC in highly experienced HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18217999     DOI: 10.1111/j.1468-1293.2007.00540.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  8 in total

1.  The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans.

Authors:  Carolina Herrera; Mackenzie L Cottrell; John Prybylski; Angela D M Kashuba; Ronald S Veazey; Javier García-Pérez; Natalia Olejniczak; Clare F McCoy; Paul Ziprin; Nicola Richardson-Harman; José Alcami; Karl R Malcolm; Robin J Shattock
Journal:  iScience       Date:  2022-05-16

2.  Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.

Authors:  Carmen Álvarez-Fernández; Alberto Crespo Guardo; Javier García-Pérez; Felipe García; Julia Blanco; Laura Escribà-García; Jose Maria Gatell; Jose Alcamí; Montserrat Plana; Sonsoles Sánchez-Palomino
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

3.  International network for comparison of HIV neutralization assays: the NeutNet report II.

Authors:  Leo Heyndrickx; Alan Heath; Enas Sheik-Khalil; Jose Alcami; Vera Bongertz; Marianne Jansson; Mauro Malnati; David Montefiori; Christiane Moog; Lynn Morris; Saladin Osmanov; Victoria Polonis; Meghna Ramaswamy; Quentin Sattentau; Monica Tolazzi; Hanneke Schuitemaker; Betty Willems; Terri Wrin; Eva Maria Fenyö; Gabriella Scarlatti
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

4.  High viral fitness during acute HIV-1 infection.

Authors:  Alicia Arnott; Darren Jardine; Kim Wilson; Paul R Gorry; Kate Merlin; Patricia Grey; Matthew G Law; Elizabeth M Dax; Anthony D Kelleher; Don E Smith; Dale A McPhee
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

5.  Infectivity of Homologous Recombinant HIV-1 Pseudo-virus with Reverse Transcriptase Inhibitor-related Mutations from Highly Active Antiretroviral Therapy Experienced Patients.

Authors:  Oh-Kyung Kwon; Ju-Yeon Choi; Eun-Jin Kim; Sung Soon Kim
Journal:  Osong Public Health Res Perspect       Date:  2011-04-14

6.  Visualization of X4- and R5-Tropic HIV-1 Viruses Expressing Fluorescent Proteins in Human Endometrial Cells: Application to Tropism Study.

Authors:  Rachel Terrasse; Meriam Memmi; Sabine Palle; Leo Heyndrickx; Guido Vanham; Bruno Pozzetto; Thomas Bourlet
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

7.  International network for comparison of HIV neutralization assays: the NeutNet report.

Authors:  Eva Maria Fenyö; Alan Heath; Stefania Dispinseri; Harvey Holmes; Paolo Lusso; Susan Zolla-Pazner; Helen Donners; Leo Heyndrickx; Jose Alcami; Vera Bongertz; Christian Jassoy; Mauro Malnati; David Montefiori; Christiane Moog; Lynn Morris; Saladin Osmanov; Victoria Polonis; Quentin Sattentau; Hanneke Schuitemaker; Ruengpung Sutthent; Terri Wrin; Gabriella Scarlatti
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240

8.  Hydroxytyrosol: a new class of microbicide displaying broad anti-HIV-1 activity.

Authors:  Luis M Bedoya; Manuela Beltrán; Patricia Obregón-Calderón; Javier García-Pérez; Humberto E de la Torre; Nuria González; Mayte Pérez-Olmeda; David Auñón; Laura Capa; Eduardo Gómez-Acebo; José Alcamí
Journal:  AIDS       Date:  2016-11-28       Impact factor: 4.177

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.